Temple University

This Week in PNAS

In PNAS this week: effector proteins contributing to Legionnaires' disease virulence, proteomic analysis of transition to quiescence, and more.

The study will use NantHealth's GPS Cancer test to help treat adult and pediatric brain cancer patients.

Two recent studies confirm that CRISPR/Cas9 can edit and inhibit latent HIV provirus, but one of them hints that the virus can develop resistance to excision.

Researchers saw higher-than-anticipated genetic diversity when they sequenced a handful of Plasmodium vivax isolates from a malaria endemic region in Colombia.

The cancer genetic non-profit has opened a new facility located at Temple University.

In the first phase of the three-part pilot program, three projects will be chosen from 10 institutions in the Philadelphia region, Delaware, and New Jersey to receive one-year grants worth as much as $200,000 for proof-of-concept studies.

News Briefs


Cerenis, Montreal Heart Institute, UVA, Ortho Clinical, Mirna, UCSF, Case Western, Diagnostic Hybrids, iBridge Network, Ben Franklin Tech Partners, and more…

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.